Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations

Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.

MT1910_Third Quarter_292136531_1200.jpg
• Source: shutterstock.com

More from Business

More from Medtech Insight